logo-loader
viewSilence Therapeutics PLC

Silence Therapeutics confirms Dr Rob Quinn as chief financial officer

"I'm very pleased that Rob will serve as full-time chief financial officer and on behalf of the board I would like to formally welcome him to this role," said David Horn Solomon, Silence's CEO

Board room
Dr Quinn is a chartered accountant and qualified at Deloitte

Silence Therapeutics PLC (LON:SLN) has given interim chief financial officer (CFO) Rob Quinn the job on a permanent basis.

Quinn has been the interim CFO since January 2019, having been the head of Financial Planning and Analysis at the company for the two years prior to getting the CFO gig.

READ Silence Therapeutics makes key new hire

“Rob's scientific and financial skills, alongside his commercial acumen make him an asset to the Silence team. During his time at the company he has continued to play an important role in building the business, with a keen appreciation for how we will grow in the future," said David Horn Solomon, the chief executive officer of the AIM-listed drugs developer.

 

Quick facts: Silence Therapeutics PLC

Price: 216 GBX

AIM:SLN
Market: AIM
Market Cap: £169.19 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Silence Therapeutics PLC named herein, including the promotion by the Company of Silence Therapeutics PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Silence Therapeutics hits first milestone in Mallinckrodt deal

Silence Therapeutics PLC's (LON:SLN) David Solomon speaks to Proactive London's Andrew Scott soon after announcing they've hit the first milestone in their deal with Mallinckrodt Pharmaceuticals - triggering a US$2mln research payment. The UK specialist in RNA therapeutics has already...

2 weeks, 5 days ago

2 min read